Google
VTGN 株価分析 — Vistagen Therapeutics Inc (Healthcare >> Biotechnology)
VTGN に関するよくある質問
VTGNのROE（自己資本利益率）は？
Vistagen Therapeutics IncのROEは-196.19%です。
VTGNの配当利回りは？
Vistagen Therapeutics Incの配当利回りは0.00%です。
VTGNの品質スコア（Quality Score）は？
当社のAIはVTGNの総合財務品質を100点中31点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
VTGNは今が買い時ですか？
当社AIのタイミングスコアは100点中28点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
VTGNはどのセクターに属しますか？
Vistagen Therapeutics IncはHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）
VTGN AI Analysis Summary
Our AI summary for VTGN: Vistagen Therapeutics Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -196.19%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 28/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 0.30
Price
-0.00
(-1.00%)
Day Change
|
|
|---|
VTGN, ファンダメンタルスコアはnot good ( ファンダメンタル = 31) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROEが昨年度比で低い
ROAがROEに比べて低い
Last-year ROA is lower than last-2-years ROA.
昨年度のROAが一昨年比で低い
NPMが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...
| Deepscope 分析 |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 84 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 0.30 |
| PBV / Sector |
0.32 / 44,105.10
GREAT
|
| Earning Per Share | -1.83 |
| PE / Sector |
N/A / 19.37
|
| PEG or PE/Growth / Sector |
N/A / 1.06
|
| Average 1M Daily Value |
2.05 M
GREAT
|
| Average 1W Daily Value |
7.46 M
|
| Timing Factors |
|
57% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
66% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-06 08:00:53 |
| Symbol | VTGN |
| Name | VISTAGEN THERAPEUTICS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 44.38 M |
| Par Value | N/A |
| Calculated From | YearEnd |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 11.31 / 9,702.21 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 343 Allerton Avenue, South San Francisco, CA, United States, 94080
Phone: 650 577 3600
Website: https://www.vistagen.com
Sector: Healthcare >> Biotechnology
Description: Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase IIa clinical trial to treat major depressive disorder. It also develops refisolone, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase IIa clinical trial for the treatment of vasomotor symptoms, including hot flashes due to menopause, premenstrual dysphoric disorder, and other women's health disorders; PH15, an investigational pherine nasal spray, which is in Phase IIa clinical trial for the treatment to improve cognitive impairment caused by mental fatigue disorders; PH284, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase IIa clinical trial to treat loss of appetite associated with chronic disorders, such as cancer cachexia; and AV-101, an oral prodrug that targets N-methyl-D-aspartate receptor in the brain for treating depression and neurological disorders. It has a license and collaboration agreement with AffaMed Therapeutics, Inc. to develop, manufacture, and commercialize fasedienol for multiple anxiety-related disorders. Vistagen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
